Equity holders face near-total loss in Chapter 11 proceedings. Monitor the bankruptcy court docket (Case No. 26-10989) for restructuring plans or liquidation motions. The lack of an auditor and OTCID Basic listing make the stock effectively untradeable for most institutional investors.
Price Chart
Executive Summary
Sangamo Therapeutics filed an 8-K disclosing the termination of Ernst & Young as its independent auditor following its Chapter 11 bankruptcy filing, and that its common stock now trades on the OTCID Basic Market under symbol SGMOQ. The company has not yet engaged a new auditor, and its Nasdaq delisting appeal remains pending โ signaling a near-total loss of equity value.
Key Facts
- Audit committee terminated Ernst & Young as independent auditor on June 25, 2026, following the company's Chapter 11 bankruptcy filing.
- No new independent registered public accounting firm has been engaged.
- Common stock began trading on the OTCID Basic Market on June 24, 2026 under symbol SGMOQ, after previously being suspended from Nasdaq and moving to OTCQB.
- Nasdaq delisting determination (due to minimum bid price non-compliance) is stayed pending appeal, but trading remains suspended on Nasdaq.
- EY's reports for fiscal years 2024 and 2025 contained a going-concern explanatory paragraph but were otherwise unqualified.
Financial Impact
Equity value is likely near zero in Chapter 11; no financial figures provided in filing.
Risk Factors
- Equity may be cancelled or receive no distribution in Chapter 11.
- Delisting from Nasdaq is likely permanent if appeal fails.
- Absence of a registered auditor may prevent timely SEC filings and further erode transparency.
- Bankruptcy proceedings could result in material dilution or conversion of debt to equity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-292501 |
| Document: d113173dex161.htm | 0001193125-26-292501 |
| Document: 0001193125-26-292501-index-headers.html | 0001193125-26-292501 |
| Document: 0001193125-26-292501-index.html | 0001193125-26-292501 |
| Document: 0001193125-26-292501.txt | 0001193125-26-292501 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 1, 2026 13w ago | 8-K | $0.0740 awaiting T+20 | awaiting T+20 | โ | โ |
Apr 29, 2026 22w ago | 8-K | $0.1300 $0.2000 | โผ โ53.85% | โผ โ48.39% | โ |
Apr 21, 2026 23w ago | Insider Cluster | $0.2600 $0.1300 | โผ โ50.00% | โผ โ54.91% | โ |
Mar 30, 2026 26w ago | Press Release | $0.2500 $0.1387 | โผ โ44.52% | โผ โ53.94% | โ |
Mar 19, 2026 28w ago | Press Release | $0.3300 $0.2700 | โผ โ18.18% | โผ โ27.50% | โ |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access